Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based […]

Continue Reading

Can CBD Help Curb COVID? Maybe, But More Study Needed

By Dennis Thompson HealthDay Reporter MONDAY, Jan. 24, 2022 — Cannabidiol, a compound derived from marijuana, appears to show promise in blocking replication of the COVID-19 virus and preventing its spread, lab and animal studies show. CBD inhibited the ability of the coronavirus to spread in human lung cell samples, and also suppressed COVID-19 infection […]

Continue Reading

Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) elicited antibodies that neutralize the Omicron variant (B.1.1.529). Data published in the peer-reviewed journal Science, includes readouts of sera data from 51 vaccinated individuals that […]

Continue Reading